| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Penta Screen (NY)
Test Code16970
CPT Codes
81512<br><strong>This test is for New York patient testing. For non-New York patient testing, use test code 15934.</strong>
Includes
AFP, unconjugated Estriol, hCG, Dimeric Inhibin A, ITA (hyperglycosylated hCG) and Maternal Risk Interpretation
Preferred Specimen
4 mL serum
Minimum Volume
1.5 mL
Instructions
For manual orders use "Maternal Serum Screen Requisition".
The Penta Screen test in pregnant women should be performed between 14.0 and 22.9 weeks gestational age, although the optimal period is 15.0-16.9 weeks. This time frame allows sufficient opportunity for further diagnostic studies if the initial Penta Screen test results are abnormal. Specimens submitted before 14.0 weeks or after 22.9 weeks gestation cannot be properly evaluated for open neural tube defects, Down syndrome or Trisomy 18.
The "Maternal Serum Screen Requisition" designed to obtain patient data and the patient's informed consent must be utilized when ordering the Penta Screen test. Because the Penta Screen test results are influenced by certain patient characteristics, the following data must be provided with the specimen in order to permit accurate interpretation of results: date of collection, patient's (maternal) date of birth, patient's estimated date of delivery, patient's weight, patient's race, patient's diabetic status (is patient insulin-dependent prior to pregnancy), number of fetuses, and whether this is a repeat sample.
The Penta Screen test in pregnant women should be performed between 14.0 and 22.9 weeks gestational age, although the optimal period is 15.0-16.9 weeks. This time frame allows sufficient opportunity for further diagnostic studies if the initial Penta Screen test results are abnormal. Specimens submitted before 14.0 weeks or after 22.9 weeks gestation cannot be properly evaluated for open neural tube defects, Down syndrome or Trisomy 18.
The "Maternal Serum Screen Requisition" designed to obtain patient data and the patient's informed consent must be utilized when ordering the Penta Screen test. Because the Penta Screen test results are influenced by certain patient characteristics, the following data must be provided with the specimen in order to permit accurate interpretation of results: date of collection, patient's (maternal) date of birth, patient's estimated date of delivery, patient's weight, patient's race, patient's diabetic status (is patient insulin-dependent prior to pregnancy), number of fetuses, and whether this is a repeat sample.
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 14 days
Refrigerated: 14 days
Frozen: 28 days
Refrigerated: 14 days
Frozen: 28 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis • Grossly lipemic
Methodology
Immunoassay (IA)
Setup Schedule
Set up: Mon-Sat; Report available: 3-5 days
Limitations
Penta Screen results consistent with an increased risk of trisomy should be confirmed with amniotic fluid specimen. Results consistent with increased risk of NTD may be followed-up with appropriate diagnostic testing as detailed in the report. Maternal serum screening yields a low percentage of false negatives. A wide range of other chromosomal abnormalities are not identified by maternal serum screening.
